On May 25, the Montreal Clinical Research Institute (IRCM) inaugurated a new clinic specializing in rare kidney diseases. Tarik Möröy, President and Scientific Director of the IRCM, also took the opportunity to announce the appointment of its director, physician and researcher Guillaume Bollée.
The Rare Kidney Diseases Clinic will be housed at the Institute’s Research Centre on Rare and Genetic Diseases in Adults. It will treat patients with various kidney diseases, including polycystic kidney disease, cystinosis, thrombotic microangiopathies, tubulopathies, tubulointerstitial kidney diseases and hereditary glomerulopathies. The research protocols that will be carried out will mainly focus on new methods of diagnosis, monitoring and treatment and aim to define a better approach for the management of patients.
“On behalf of the IRCM community, I would like to welcome Dr. Bollée,” said Dr. Möröy. “His experience and expertise are in line with our strategic plan, in which the Institute aims to become a reference in rare and genetic diseases research. The opening of a clinic specializing in rare kidney diseases will also allow us to benefit from the contribution of Marie Trudel, a specialist in polycystic kidney disease and the Director of the IRCM’s Molecular Genetics and Development Research Unit, and it will enable us to further diversify the Institute’s expertise in this area.”
“I am delighted to welcome Dr. Bollée to the IRCM Clinic,” said Yves Berthiaume, Vice President, Clinic and Clinical Research, at the IRCM. “He will further enhance the Institute's expertise in the development of care for patients with rare and genetic diseases, particularly in terms of transitional care for patients leaving pediatric hospitals for adult hospitals.”
Launched in 2016, IRCM's Research Centre on Rare and Genetic Diseases in Adults also includes a clinic specialized in primary immunodeficiency. The Centre focuses on research, both in the laboratory and in the clinical setting, to better understand these diseases and, consequently, develop new treatments. Its ultimate goal is to provide an environment where patients will be supported by a multidisciplinary team and enjoy a better quality of life through the benefits of research.
Guillaume Bollée is a nephrologist. He also practises medicine at the Centre hospitalier de l’Université de Montréal (CHUM) and is an Assistant Clinical Professor in the Department of Medicine at the Faculty of Medicine of Université de Montréal. Dr. Bollée is the author and co-author of numerous articles in nephrology and in rare and genetic renal disease issues. He studied medicine in France at the University of Caen, in Normandie and the Université of Paris 6, and completed his medical training in Paris hospitals. Thereafter, Dr. Bollée specialized in nephrology at the University of Paris 6, and furthered his training in adult nephrology at the Hôpital Necker, in Paris. He also completed a PhD in biology at the University of Paris 7.